PEG vs. sennosides for opioid-induced constipation in cancer care.
Purpose: This randomized double-blind, double-dummy, 2-treatment, 2-period crossover study aimed to compare the efficacy and tolerability of polyethylene glycol (PEG) and sennosides in ambulatory cancer patients with opioid-induced constipation.Methods: Outpatients ≥ 18 years old with cancer, at ris...
| Publicado en: | Supportive Care in Cancer Vol. 28; no. 4; pp. 1775 - 1783 |
|---|---|
| Autores principales: | , , |
| Formato: | research randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Apr2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141881601&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 141881601 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09414355 O1J jtl: Supportive Care in Cancer issn: 09414355 maglogo: N pubinfo: dt: Apr2020 vid: 28 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 141881601 141881601 NLM31321524 141881601 10.1007/s00520-019-04944-5 NLM31321524 141881601 ppf: 1775 ppct: 8 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: PEG vs. sennosides for opioid-induced constipation in cancer care. aug: au: Hawley, Philippa MacKenzie, Hannah Gobbo, Monica affil: Pain and Symptom Management/Palliative Care, British Columbia Cancer, 600 W 10th Ave, V5Z 4E6, Vancouver, BC, Canada sug: subj: Neoplasms Drug Therapy Polyethylene Glycols Therapeutic Use Patient Satisfaction Human Male Female Treatment Outcomes Crossover Design Double-Blind Studies Middle Age Aged Cathartics Therapeutic Use Young Adult Defecation Drug Effects Aged, 80 and Over Analgesics, Opioid Adverse Effects Adult Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over Adult: 19-44 years Male Female ab: Purpose: This randomized double-blind, double-dummy, 2-treatment, 2-period crossover study aimed to compare the efficacy and tolerability of polyethylene glycol (PEG) and sennosides in ambulatory cancer patients with opioid-induced constipation.Methods: Outpatients ≥ 18 years old with cancer, at risk of or already experiencing opioid-induced constipation, were randomly assigned to begin a standard bowel protocol of escalating doses of sennosides or PEG, plus a dummy preparation. After 3 weeks, the patients switched to the alternate active product and dummy preparation. Constipation was assessed using the revised Victoria Bowel Performance Scale (rBPS) at the end of each of the 2 consecutive 21-day study periods for the number of days with a satisfactory bowel movement, the time in days to goal rBPS (G), and the treatment preference of each patient.Results: Seventy patients were recruited, with 42 completing their first treatment period and 28 completing both treatment periods. For the typical patient, the expected number of days with a satisfactory bowel movement per days of treatment was found to be 1.21 times higher on PEG than on sennosides in a particular period (95% credible interval 0.96 to 1.55). Patients taking PEG were 1.47 times more likely to reach a rBPS of G before patients taking sennosides in the first period (95% confidence interval 0.74 to 2.94). There was no evidence of a difference in patient preference between laxatives.Conclusion: Our study found weak evidence that PEG is superior to sennosides with respect to overall effectiveness in cancer patients with opioid-induced constipation. pubtype: Academic Journal doctype: research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|